Healthcare / Drug Manufacturers - Specialty & GenericASX
$0.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-25.9M · quality 35.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
0.4x
↓EV/EBITDA
N/A
•ROE
-368.1%
↓Gross Margin
100.0%
↑Debt/Equity
5.21
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+53.0%
FCF CAGR
—
FCF margin
-115.1%
FCF / Net income
0.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.4M · net income $-51.2M · FCF $-17.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.4M | $15.4M | $13.8M | $6.4M | $4.3M |
| Net Income | $-51.2M | $-51.2M | $-33.8M | $-26.5M | $-25.1M |
| EBITDA | $-33.4M | $-33.4M | $-18.7M | $-19.8M | $-18.3M |
| EPS | -0.11 | -0.11 | -0.09 | -0.07 | -0.09 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 98.9% |
| Operating Margin | -178.9% | -178.9% | -265.5% | -453.5% | -548.5% |
| Net Margin | -333.3% | -333.3% | -245.3% | -412.9% | -584.7% |
| Balance Sheet | |||||
| Debt/Equity | 5.21 | 5.21 | 1.03 | 0.56 | 0.01 |
| Current Ratio | 0.42 | 0.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-17.7M | $-17.7M | $-25.9M | $-65.6M | $-37.1M |
| Returns | |||||
| ROE | -368.1% | -368.1% | -57.0% | -31.2% | -27.3% |
| Valuation | |||||
| P/E | 0.40 | 0.40 | — | — | — |
| P/B | 0.13 | 0.13 | 0.86 | 1.25 | 1.24 |
| Growth & Yield | |||||
| Revenue Growth | 11.6% | 11.6% | 114.9% | 49.3% | — |
| EPS Growth | -31.4% | -31.4% | -15.9% | 19.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-69.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.09 → -0.11
Residual
-69.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.